Anaplastic Malignant Neoplasm

cancer family

Identifier: CI-CAN-00000065
Entity page: /cancer/anaplastic-malignant-neoplasm ↗
Edges: 2,345

Neighbours: 15 genes16 drugs10 trials
Drawn: 41 of 41 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Anaplastic Malignant Neoplasm approved for …APPROVED_FORderived15 of 21show all (up to 200)
← approved for	Crizotinibsmall molecule FDA (US) · approved · 2023-09-07 · pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) tha…	—	approved	Anaplastic Large Cell Lymphoma	1	Regulatory	openfda	graph →
approved for

Anaplastic Malignant Neoplasm altered in cohorts of …ALTERED_INderived15 of 99show all (up to 200)
← altered in cohorts of	PTEN 461 / 601 cases (77 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	ATRNL1 456 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	MYOF 456 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	SEC23IP 456 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	BAG3 455 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	CACUL1 455 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	EGFR 455 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	EIF3A 455 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	INPP5F 455 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	MCMBP 455 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	PRLHR 455 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	SORBS1 455 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	ACTA2 454 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	CTBP2 454 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	CYP26C1 454 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →

Anaplastic Malignant Neoplasm altered in cohorts of …ALTERED_INderived15 of 99show all (up to 200)

← altered in cohorts of

PTEN

461 / 601 cases (77 %) · ssm · TCGA-GBM

—

Glioblastoma

Observed

Anaplastic Malignant Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 206show all (up to 200)
→ investigated in trials for	Temozolomidesmall molecule 308 trials (100 active) · roll-up of the cancer and its descendants	—	—	Anaplastic Malignant Neoplasm	308	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 126 trials (20 active) · roll-up of the cancer and its descendants	—	—	Anaplastic Malignant Neoplasm	126	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 46 trials (28 active) · roll-up of the cancer and its descendants	—	—	Anaplastic Malignant Neoplasm	46	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 42 trials (23 active) · roll-up of the cancer and its descendants	—	—	Anaplastic Malignant Neoplasm	42	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 41 trials (13 active) · roll-up of the cancer and its descendants	—	—	Anaplastic Malignant Neoplasm	41	Observed	clinicaltrials	graph →
→ investigated in trials for	Lomustinesmall molecule 39 trials (12 active) · roll-up of the cancer and its descendants	—	—	Anaplastic Malignant Neoplasm	39	Observed	clinicaltrials	graph →
→ investigated in trials for	Etoposidesmall molecule 28 trials (5 active) · roll-up of the cancer and its descendants	—	—	Anaplastic Malignant Neoplasm	28	Observed	clinicaltrials	graph →
→ investigated in trials for	Fludarabinesmall molecule 28 trials (6 active) · roll-up of the cancer and its descendants	—	—	Anaplastic Malignant Neoplasm	28	Observed	clinicaltrials	graph →
→ investigated in trials for	Ipilimumabmonoclonal antibody 27 trials (15 active) · roll-up of the cancer and its descendants	—	—	Anaplastic Malignant Neoplasm	27	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 22 trials (4 active) · roll-up of the cancer and its descendants	—	—	Anaplastic Malignant Neoplasm	22	Observed	clinicaltrials	graph →
→ investigated in trials for	Vorinostatsmall molecule 19 trials (1 active) · roll-up of the cancer and its descendants	—	—	Anaplastic Malignant Neoplasm	19	Observed	clinicaltrials	graph →
→ investigated in trials for	Irinotecansmall molecule 18 trials (4 active) · roll-up of the cancer and its descendants	—	—	Anaplastic Malignant Neoplasm	18	Observed	clinicaltrials	graph →
→ investigated in trials for	Brentuximab Vedotinadc 16 trials (4 active) · roll-up of the cancer and its descendants	—	—	Anaplastic Malignant Neoplasm	16	Observed	clinicaltrials	graph →
→ investigated in trials for	Carmustinesmall molecule 16 trials (1 active) · roll-up of the cancer and its descendants	—	—	Anaplastic Malignant Neoplasm	16	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 16 trials (2 active) · roll-up of the cancer and its descendants	—	—	Anaplastic Malignant Neoplasm	16	Observed	clinicaltrials	graph →

Anaplastic Malignant Neoplasm studied in …STUDIED_INderived10 of 2,019show all (up to 200)
→ studied in	NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped ONTOLOGY_EXACT · 2,019 trials mapped (611 active)	—	—	Invasive Bladder Sarcomatoid Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05685004Phase 2/Phase 3 · active not recruiting Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) · condition mapped ALIAS · 2,019 trials mapped (611 active)	—	—	Brain Glioblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05864534Phase 2 · active not recruiting Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma · condition mapped CURATED_BROADER · 2,019 trials mapped (611 active)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05871021Phase 2 · active not recruiting Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma · condition mapped CURATED_BROADER · 2,019 trials mapped (611 active)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05902169Phase 3 · recruiting Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM · condition mapped CURATED_BROADER · 2,019 trials mapped (611 active)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06325683Phase 2 · suspended Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma · condition mapped CURATED_BROADER · 2,019 trials mapped (611 active)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07005297not yet recruiting Clinical Genetics Branch Eligibility Screening Survey · condition mapped ONTOLOGY_EXACT · 2,019 trials mapped (611 active)	—	—	Pulmonary Blastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05303467Phase 1 · recruiting A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM · condition mapped CURATED_BROADER · 2,019 trials mapped (611 active)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05432804Phase 1/Phase 2 · recruiting Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment · condition mapped CURATED_BROADER · 2,019 trials mapped (611 active)	—	—	Glioblastoma, IDH-Wildtype	1	Observed	clinicaltrials	graph →
→ studied in	NCT07145112Phase 1 · recruiting Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma · condition mapped CURATED_BROADER · 2,019 trials mapped (611 active)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains